Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

Abstract

Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy thought to have an antiangiogenic basis. However, the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term in this way with targeted therapies can be compromised by the empiricism associated with… (More)

Topics

Cite this paper

@article{Shaked2005OptimalBD, title={Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.}, author={Yuval Shaked and Urban Emmenegger and S. G. K. Man and Dave Cervi and Francesco Bertolini and Yaacov Ben-David and Robert S. Kerbel}, journal={Blood}, year={2005}, volume={106 9}, pages={3058-61} }